Physician profile
Michael Mchugh
NPI 1770281677
$4,378.27
in general payments reported to CMS, 2019-2025
13 companies · $2,645 in 2025
The $2,645 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $651 · 2024: $1,082 · 2025: $2,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,981 · Travel and Lodging: $997 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,981.43 |
| Travel and Lodging | $996.84 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,510.91 | 2024-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $881.84 | 2023-2025 | Optimizer, Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $634.06 | 2024-2025 | |
| Abbott Laboratories | $474.22 | 2023-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Merck Sharp & Dohme LLC | $331.06 | 2023-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $192.03 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $75.97 | 2024-2025 | Farxiga, Wainua |
| Pfizer INC. | $71.56 | 2025 | |
| Scpharmaceuticals INC. | $69.71 | 2024 | |
| Novartis Pharmaceuticals Corporation | $50.27 | 2024-2025 | |
| Abiomed | $42.27 | 2024 | Impella |
| Bridgebio Pharma, INC. | $29.18 | 2025 | Attruby |
| Kiniksa Pharmaceuticals, LTD. | $15.19 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mchugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.